Delisting risk
CNS Pharmaceuticals
Seeks to acquire or in-license neurology and oncology drug candidates.
$5.75
After-hours close+0.23 (+4.11%)
At close$5.52(+0.10%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 9.96%145.6K sharesInsiders 0.95%13.9K sharesOther 89.09%1.30M shares
Shares outstanding 1.46M · Float 1.45M · 99.2% free float
Institutions13F, as of Mar 31, 2026
11 holders · 145.6K shares · 4 new positions · 6 increased · 0 reduced · 2 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Stonepine Capital Management, LLC | 61.0K | 4.17% | +12.2K | May 14, 2026 |
| Ikarian Capital, LLC | 45.8K | 3.14% | 0 | May 15, 2026 |
| Geode Capital Management, LLC | 23.2K | 1.59% | +23.2Knew | May 15, 2026 |
| Boothbay Fund Management, LLC | 13.5K | 0.93% | 0 | May 15, 2026 |
| Tower Research Capital LLC (TRC) | 1.3K | 0.09% | +1.3Knew | May 15, 2026 |
| UBS Group AG | 729 | 0.05% | +118 | May 5, 2026 |
| Barrett & Company, Inc. | 8 | 0.00% | 0 | May 4, 2026 |
| Mai Capital Management | 3 | 0.00% | 0 | May 15, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Stonepine Capital Management, LLC | 9.90% | 159.8K | 13G | May 15, 2026 ↗ |
| Ikarian Capital, LLC | 5.70% | 45.8K | 13G | Apr 17, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Faith L. Charles | director | 7.1K | 0.49% | May 20, 2026 |
| Rami Levin | officer: CEO and President | 4.8K | 0.33% | Aug 18, 2026 |
| Michal Fisher | director | 2.0K | 0.14% | Aug 18, 2026 |
2 ten-percent owners hold 961 shares by Form 4, outside the officers-and-directors figure above · 5 people have not refiled in the last 18 months (13 shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| May 18, 2026 | Michal Fisherdirector | Purchase | 2,000 | $5.00 | 2,000 |
| May 18, 2026 | Faith L. Charlesdirector | Purchase | 7,100 | $4.79 | 7,100 |
CongressHouse and Senate disclosures
Not reported.